Indirect Effects of Pneumococcal Conjugate Vaccines in National Immunization Programs for Children on Adult Pneumococcal Disease

키워드

참고문헌 (64)

1. Anonymous, "Pneumococcal conjugate vaccine for childhood immunization--WHO position paper", Wkly Epidemiol Rec, 82, pp.93~104 (2007)
2. Anonymous, "Pneumococcal vaccines WHO position paper--2012", Wkly Epidemiol Rec, 87, pp.129~144 (2012)
3. Anonymous, "23-valent pneumococcal polysaccharide vaccine. WHO position paper", Wkly Epidemiol Rec, 83, pp.373~384 (2008)
4. Janoff EN, "Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases", pp.2310~2327 (2015), Elsevier
5. Backhaus E, "Epidemiology of invasive pneumococcal infections: manifestations, incidence, and case fatality rate correlated to age, gender, and risk factors", BMC Infect Dis, 16, pp.367~ (2016)
6. Navarro-Torné A, "Risk factors for death from invasive pneumococcal disease, Europe, 2010", Emerg Infect Dis, 21, pp.417~425 (2015)
7. Kaplan SL, "Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine", Pediatr Infect Dis J, 32, pp.203~207 (2013)
8. Whitney CG, "Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine", N Engl J Med, 348, pp.1737~1746 (2003)
9. Papadatou I, "Pneumococcal vaccination in high-risk individuals: are we doing it right?", Clin Vaccine Immunol, 23, pp.388~395 (2016)
10. Stein KE, "Thymus-independent and thymus-dependent responses to polysaccharide antigens", J Infect Dis, 165(Suppl 1), pp.S49~S52 (1992)
11. Tomczyk S, "Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65years: recommendations of the Advisory Committee on Immunization Practices (ACIP)", MMWR Morb Mortal Wkly Rep, 63, pp.822~825 (2014)
12. Centers for Disease Control and Prevention, "Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003", MMWR Morb Mortal Wkly Rep, 54, pp.893~897 (2005)
13. Kellner JD, "Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study", Clin Infect Dis, 49, pp.205~212 (2009)
14. von Gottberg A, "Effects of vaccination on invasive pneumococcal disease in South Africa", N Engl J Med, 371, pp.1889~1899 (2014)
15. Geno KA, "Pneumococcal capsules and their types: past, present, and future", Clin Microbiol Rev, 28, pp.871~899 (2015)
16. "Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof"[URL]
17. "Immunization, vaccines, and biologicals: Data, statistics and graphics"[URL]
18. "Vaccine in national immunization programme update"[URL]
19. 조은영, "Changes in Serotype Distribution and Antibiotic Resistance of Nasopharyngeal Isolates of Streptococcus pneumoniae from Children in Korea, after Optional Use of the 7-Valent Conjugate Vaccine", Journal of Korean Medical Science, 27(7), pp.716~722 (2012), 대한의학회[DOI]
20. "2013 Korea National Immunization Survey"[URL]
21. 최원석, "Revised Adult Immunization Guideline Recommended by the Korean Society of Infectious Diseases, 2014", Infection and Chemotherapy, 47(1), pp.68~79 (2015), 대한감염학회
22. Gray BM, "Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life", J Infect Dis, 142, pp.923~933 (1980)
23. Faden H, "Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda", Williamsville Pediatrics, 1997, pp.175, 1440~1445
24. Simell B, "The fundamental link between pneumococcal carriage and disease", Expert Rev Vaccines, 11, pp.841~855 (2012)
25. 송준영, "Clinical Implications of Pneumococcal Serotypes: Invasive Disease Potential, Clinical Presentations, and Antibiotic Resistance", Journal of Korean Medical Science, 28(1), pp.4~15 (2013), 대한의학회
26. Avery OT, "The protective action of a specific enzyme against type III pneumococcus infection in mice", J Exp Med, 54, pp.73~89 (1931)
27. Hausdorff WP, "Epidemiological differences among pneumococcal serotypes", Lancet Infect Dis, 5, pp.83~93 (2005)
28. Briles DE, "Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae", Infect Immun, 60, pp.111~116 (1992)
29. Bogaert D, "Streptococcus pneumoniae colonisation: the key to pneumococcal disease", Lancet Infect Dis, 4, pp.144~154 (2004)
30. Bogaert D, "Pneumococcal carriage in children in The Netherlands: a molecular epidemiological study", J Clin Microbiol, 39, pp.3316~3320 (2001)
31. Givon-Lavi N, "Spread of Streptococcus pneumoniae and antibiotic-resistant S. pneumoniae from day-care center attendees to their younger siblings", J Infect Dis, 186, pp.1608~1614 (2002)
32. 김선미, "국내 소아의 비강 내 폐구균 보균율과 혈청형에 관한 역학연구", Korean Journal of Pediatrics, 47(6), pp.611~616 (2004), 대한소아과학회
33. Dowell SF, "Seasonal patterns of invasive pneumococcal disease", Emerg Infect Dis, 9, pp.573~579 (2003)
34. Walter ND, "Holiday spikes in pneumococcal disease among older adults", N Engl J Med, 361, pp.2584~2585 (2009)
35. Rodrigo C, "Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status", Thorax, 69, pp.168~173 (2014)
36. Dagan R, "Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers", J Infect Dis, 185, pp.927~936 (2002)
37. Millar EV, "Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members", Clin Infect Dis, 47, pp.989~996 (2008)
38. Roca A, "Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial", PLoS Med, 8, pp.e1001107~ (2011)
39. Nzenze SA, "Temporal changes in pneumococcal colonization in a rural African community with high HIV prevalence following routine infant pneumococcal immunization", Pediatr Infect Dis J, 32, pp.1270~1278 (2013)
40. Hammitt LL, "Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies", Lancet Glob Health, 2, pp.e397~e405 (2014)
41. Cohen R, "Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media", Pediatr Infect Dis J, 31, pp.297~301 (2012)
42. Loughlin AM, "Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts'children", Pediatr Infect Dis J, 33, pp.504~510 (2014)
43. Davis SM, "Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people:review of evidence on indirect effects", Vaccine, 32, pp.133~145 (2013)
44. Feikin DR, "Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites", PLoS Med, 10, pp.e1001517~ (2013)
45. Pilishvili T, "Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine", J Infect Dis, 201, pp.32~41 (2010)
46. Myint TT, "The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review", Adv Ther, 30, pp.127~151 (2013)
47. Cabaj JL, "Influence of childhood pneumococcal conjugate vaccines on invasive pneumococcal disease in adults with underlying comorbidities in Calgary, Alberta (2000-2013)", Clin Infect Dis, 62, pp.1521~1526 (2016)
48. Harboe ZB, "Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality", Clin Infect Dis, 59, pp.1066~1073 (2014)
49. Kendall BA, "Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children", Vaccine, 34, pp.474~478 (2016)
50. Moore CE, "Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England", J Infect Dis, 210, pp.1001~1011 (2014)
51. Moore MR, "Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA:analysis of multisite, population-based surveillance", Lancet Infect Dis, 15, pp.301~309 (2015)
52. Waight PA, "Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study", Lancet Infect Dis, 15, pp.535~543 (2015)
53. Miller E, "Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study", Lancet Infect Dis, 11, pp.760~768 (2011)
54. Regev-Yochay G, "Early impact of PCV7", PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study, 2015, pp.33, 1135~1142
55. Greenberg D, "Editorial commentary: pneumococcal vaccination in adults: Do we have to recalculate our approach?", Clin Infect Dis, 62, pp.1527~1528 (2016)
56. Andrews NJ, "Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study", Lancet Infect Dis, 14, pp.839~846 (2014)
57. Horácio AN, "Serotype 3 remains the leading cause of invasive pneumococcal disease in adults in Portugal (2012–2014) despite continued reductions in other 13-valent conjugate vaccine serotypes", Front Microbiol, 7, pp.1616~ (2016)
58. Said MA, "Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques", PLoS One, 8, pp.e60273~ (2013)
59. Pletz MW, "Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay", Vaccine, 34, pp.2342~2348 (2016)
60. Rodrigo C, "Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia", Eur Respir J, 45, pp.1632~1641 (2015)
61. Bonten MJ, "Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults", N Engl J Med, 372, pp.1114~1125 (2015)
62. van Werkhoven CH, "Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly", Vaccine, 34, pp.3275~3282 (2016)
63. Kim SH, "Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP)study", Antimicrob Agents Chemother, 56, pp.1418~1426 (2012)
64. Kraicer-Melamed H, "The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23)in the general population of 50 years of age and older: a systematic review and meta-analysis", Vaccine, 34, pp.1540~1550 (2016)

관련 논문AI추천